| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ... The Lancet 364 (9440), 1127-1134, 2004 | 2104 | 2004 |
| American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: Update 2003 DG Pfister, DH Johnson, CG Azzoli, W Sause, TJ Smith, S Baker Jr, J Olak, ... Journal of Clinical Oncology 22 (2), 330-353, 2004 | 1904 | 2004 |
| American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Baker Jr, S Temin, W Pao, T Aliff, J Brahmer, DH Johnson, ... Journal of clinical oncology 27 (36), 6251, 2009 | 974 | 2009 |
| The genomic landscape of hypodiploid acute lymphoblastic leukemia L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, ... Nature genetics 45 (3), 242-252, 2013 | 788 | 2013 |
| CREBBP mutations in relapsed acute lymphoblastic leukaemia CG Mullighan, J Zhang, LH Kasper, S Lerach, D Payne-Turner, ... Nature 471 (7337), 235-239, 2011 | 697 | 2011 |
| Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update GA Masters, S Temin, CG Azzoli, G Giaccone, S Baker Jr, JR Brahmer, ... Journal of Clinical Oncology 33 (30), 3488, 2015 | 547 | 2015 |
| Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. American Society of Clinical Oncology Journal of Clinical Oncology 15 (8), 2996-3018, 1997 | 494 | 1997 |
| 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Temin, T Aliff, S Baker Jr, J Brahmer, DH Johnson, JL Laskin, ... Journal of clinical oncology 29 (28), 3825-3831, 2011 | 432 | 2011 |
| Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes J Li, M Zhao, P He, M Hidalgo, SD Baker Clinical Cancer Research 13 (12), 3731-3737, 2007 | 341 | 2007 |
| Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001 SD Baker, J Verweij, EK Rowinsky, RC Donehower, JHM Schellens, ... Journal of the National Cancer Institute 94 (24), 1883-1888, 2002 | 326 | 2002 |
| Irinotecan pathway genotype analysis to predict pharmacokinetics RHJ Mathijssen, S Marsh, MO Karlsson, R Xie, SD Baker, J Verweij, ... Clinical cancer research 9 (9), 3246-3253, 2003 | 325 | 2003 |
| Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy C Niyikiza, SD Baker, DE Seitz, JM Walling, K Nelson, JJ Rusthoven, ... Molecular cancer therapeutics 1 (7), 545-552, 2002 | 322 | 2002 |
| An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors ML Amador, D Oppenheimer, S Perea, A Maitra, G Cusati, ... Cancer Research 64 (24), 9139-9143, 2004 | 311 | 2004 |
| Absorption, Metabolism, and Excretion of 14C-Temozolomide following Oral Administration to Patients with Advanced Cancer SD Baker, M Wirth, P Statkevich, P Reidenberg, K Alton, SE Sartorius, ... Clinical Cancer Research 5 (2), 309-317, 1999 | 310 | 1999 |
| A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies J Gilbert, SD Baker, MK Bowling, L Grochow, WD Figg, Y Zabelina, ... Clinical Cancer Research 7 (8), 2292-2300, 2001 | 302 | 2001 |
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib G Cusatis, V Gregorc, J Li, A Spreafico, RG Ingersoll, J Verweij, ... Journal of the National Cancer Institute 98 (23), 1739-1742, 2006 | 285 | 2006 |
| Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial K Tanabe, PW Serruys, M Degertekin, E Grube, G Guagliumi, W Urbaszek, ... Circulation 111 (7), 900-905, 2005 | 267 | 2005 |
| Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel MO Bradley, NL Webb, FH Anthony, P Devanesan, PA Witman, ... Clinical Cancer Research 7 (10), 3229-3238, 2001 | 264 | 2001 |
| Interaction of imatinib with human organic ion carriers S Hu, RM Franke, KK Filipski, C Hu, SJ Orwick, EA De Bruijn, H Burger, ... Clinical Cancer Research 14 (10), 3141-3148, 2008 | 263 | 2008 |
| The influence of protein binding upon tissue fluid levels of six β-lactam antibiotics R Wise, AP Gillett, B Cadge, SR Durham, S Baker Journal of Infectious Diseases 142 (1), 77-82, 1980 | 218 | 1980 |
